NCT00946699已完成1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 14
- 主要终点
- The safety and tolerability of MEDI-551 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.
研究概览
简要总结
The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-551 over escalating single doses in adult subjects with Scleroderma
详细描述
To evaluate the safety and tolerability of escalating single IV doses of MEDI-551 in adult subjects with scleroderma who have at least moderate skin thickening in an area suitable for repeat biopsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects
- •Age ≥ 18 years of age at the time of screening
- •Written informed consent and HIPAA authorization (applies to covered entities in the USA only) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
- •Must fulfill the American Rheumatism Association (American College of Rheumatology) preliminary classification criteria for systemic sclerosis
- •Has at least moderate skin thickening (score of at least 2 by mRTSS) in at least one area suitable for repeat biopsy, such as on the arms, legs, or trunk
- •Females of childbearing potential, unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), has sterile male partner, is at least 2 years post menopause, or practices abstinence, must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the sexual partner), from screening, and must agree to continue using such precautions through the Early Discontinuation Visit/End of Study (Day 85, single-dose cohorts); cessation of birth control should not occur until 5 half-lives post-cessation of MEDI-551, 5 half-lives is estimated to be 75 days
- •Men, unless surgically sterile, must use 2 effective methods of birth control with a female partner and must agree to continue using such contraceptive precautions from Day 1 through the Early Discontinuation Visit/End of Study (Day 85, single-dose cohorts) and for 5 half-lives post-cessation of MEDI-551, 5 half-lives is estimated to be 75 days
- •Ability to complete the study period, including follow-up period through Day 85
- •Willingness to forego other forms of experimental treatment during the study (Day 1 through the Early Discontinuation Visit/End of Study - Day 85, single-dose cohorts)
排除标准
- •History of allergic reactions to any component of the investigational product
- •History of coagulation disorders that in the opinion of the investigator would contraindicate skin biopsies
- •Has a body weight ≥ 120 kg or < 40 kg
- •Has B-cell count in peripheral blood < 50% lower limit of normal (LLN) at screening
- •Forced vital capacity (FVC) < 55% predicted, diffusing capacity for carbon monoxide (DLCO) < 40% predicted, pulmonary hypertension requiring treatment with endothelin receptor antagonists or prostacyclin analogues
- •Scleroderma renal crisis within the last year, or medically significant malabsorption
- •Receipt of any B-cell-depleting biologic therapies at any time, such as rituximab
- •Receipt of leflunomide > 20 mg/day within 6 months prior to randomization into the study
- •Receipt of the following concomitant medications within 21 days prior to randomization into the study:
- •Prednisone > 30 mg/day or > 0.5 mg/kg
- •Cyclophosphamide
- •Systemic cyclosporine
- •Thalidomide
- •Hydroxychloroquine > 600 mg/day
- •Mycophenolate mofetil > 3 g/day
- •Methotrexate > 25 mg/week
- •Azathioprine > 3 mg/kg/day
- •Concomitant methotrexate and leflunomide
- •Any investigational drug therapy or non-B-cell-depleting biologic therapy (or within 5 half-lives of ingestion, whichever is longer)
- •Change in standing daily dosage of the following within 21 days before randomization into the study:
- •Antimalarials
- •Mycophenolate mofetil
- •Methotrexate
- •Leflunomide
- •Azathioprine
- •Systemic corticosteroids
- •At screening blood tests (within 21 days prior to randomization into the study), any of the following:
- •Aspartate aminotransferase (AST) > 1.5 × upper limit of the normal range (ULN)unless due to documented myositis
- •Alanine aminotransferase (ALT) > 1.5 × ULN unless due to documented myositis
- •Total bilirubin > ULN, unless because of known Gilbert's disease - Total immunoglobin <500 mg/dl
- •Creatinine > 2.5 mg/dL
- •Neutrophils < 1,500/mm3
- •Platelet count < 75,000/mm3
- •Hemoglobin (Hgb) < 8 g/dL
- •Hemoglobin A1c (HbA1c) > 8% at screening (diabetic subjects only)
- •Positive serum βHCG (pregnancy test)
- •Lactating woman
- •Herpes zoster infection within 3 months before randomization
- •A history of severe viral infection as judged by the investigator, including severe infections of either cytomegalovirus or the herpes family such as disseminated herpes, herpes encephalitis, ophthalmic herpes
- •At screening, positive tests for active hepatitis A, hepatitis B surface antigen (HbsAg), Hepatitis B core antibody (HbcAb) or hepatitis C serology, or human immunodeficiency virus-1 or -2 (HIV-1/2). False positive tests are not included.
- •Deep space/tissue infection (eg, fasciitis, abscess, osteomyelitis, or infected joint replacements) within 1 year before randomization into the study
- •Any opportunistic infection or serious infection (in the opinion of the investigator) within 6 months prior to screening
- •Any of the following within 21 days before randomization into the study:
- •Clinically significant active infection, including ongoing, chronic infection
- •Any infection requiring hospitalization or treatment with IV anti-infectives
- •Completion of a course of oral anti-infectives within 14 days before randomization into the study
- •Any acute illness or evidence of clinically significant active infection, such as fever ≥ 38.0 degrees C (≥ 100.5 degrees F) at screening or at Day 1
- •Evidence of active tuberculosis (TB), either treated or untreated, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment. Evaluation and treatment will be according to the local standard of care and may consist of history and physical examinations, and/or chest X ray, and/or TB test (eg. purified protein derivative) testing, with the standard of care as determined by local guidelines
- •History of primary immunodeficiency or underlying condition that predisposes the subject to infection (eg, splenectomy)
- •Receipt of any live or attenuated vaccine within 21 days before randomization into the study or anticipated to be given within 5 half-lives of the last dose of investigational product administration, half-life is estimated to be approximately 15 days. Therefore, receipt of live attenuated vaccine should be avoided for 75 days post dose of investigational product
- 另有 10 项未显示
结局指标
主要结局
The safety and tolerability of MEDI-551 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.
时间窗: Day 85
次要结局
- The secondary endpoints of the study are to assess the PK, IM, and PD of single IV doses of MEDI-551 in adult subjects with scleroderma. Pharmacodynamics will be assessed by numbers of B cells in blood and skin.(Day 85)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)LupusNCT00299819MedImmune LLC45
Unknown
1 期
A Pilot Study of FFP104 in Subjects With Crohn's DiseaseCrohn's DiseaseNCT02465944Fast Forward Pharmaceuticals24
Unknown
1 期
IMM-BCP-01 in Mild to Moderate COVID-19SARS-CoV2 InfectionCOVID-19NCT05429021Immunome, Inc.36
已完成
1 期
Study of NAV-240 in Healthy VolunteersNCT06181786Navigator Medicines, Inc.40
已完成
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian ParticipantsHealthy VolunteersNCT04571424Biogen33